{
    "id": 7565,
    "fullName": "EP300 inact mut",
    "impact": "unknown",
    "proteinEffect": "loss of function",
    "geneVariantDescriptions": [
        {
            "description": "EP300 inact mut indicates that this variant results in a loss of function in the Ep300 protein. However, the specific amino acid change has not been identified.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "category",
    "gene": {
        "id": 2033,
        "geneSymbol": "EP300",
        "terms": [
            "EP300",
            "KAT3B",
            "MKHK2",
            "p300",
            "RSTS2"
        ]
    },
    "variant": "inact mut",
    "createDate": "06/12/2015",
    "updateDate": "08/27/2017",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 20656,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, treatment with Mocetinostat (MGCD0103) demonstrated limited activity in patients with metastatic urothelial carcinoma harboring inactivating mutations in either EP300 or CREBBP, resulting in a partial response in 1 of 9 evaluable patients, a median progression-free survival of 57 days, progression-free survival at 4 months of 10%, and a median overall survival of 3.5 months (PMID: 30570744; NCT02236195).",
            "molecularProfile": {
                "id": 7445,
                "profileName": "EP300 inact mut"
            },
            "therapy": {
                "id": 3002,
                "therapyName": "Mocetinostat",
                "synonyms": null
            },
            "indication": {
                "id": 2671,
                "name": "transitional cell carcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 17978,
                    "pubMedId": 30570744,
                    "title": "Mocetinostat for patients with previously treated, locally advanced/metastatic urothelial carcinoma and inactivating alterations of acetyltransferase genes.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30570744"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        }
    ],
    "molecularProfiles": [
        {
            "id": 7445,
            "profileName": "EP300 inact mut",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}